BioCity has since launched a phase 3 trial of SC0062 in Chinese patients with IgAN, while a late-stage multiregional study is also in the works. “SC0062 is a best-in-class, highly selective ...
Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback